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Introduction: Indeterminate pulmonary nodules (IPNs) lack clinical 
or radiographic features of benign etiologies and often undergo inva-
sive procedures unnecessarily, suggesting potential roles for diag-
nostic adjuncts using molecular biomarkers. The primary objective 
was to validate a multivariate classifier that identifies likely benign 
lung nodules by assaying plasma protein expression levels, yielding 
a range of probability estimates based on high negative predictive 
values (NPVs) for patients with 8 to 30 mm IPNs.
Methods: A retrospective, multicenter, case-control study was per-
formed using multiple reaction monitoring mass spectrometry, a clas-
sifier comprising five diagnostic and six normalization proteins, and 
blinded analysis of an independent validation set of plasma samples.
Results: The classifier achieved validation on 141 lung nodule-
associated plasma samples based on predefined statistical goals to 
optimize sensitivity. Using a population based nonsmall-cell lung 
cancer prevalence estimate of 23% for 8 to 30 mm IPNs, the classi-
fier identified likely benign lung nodules with 90% negative predic-
tive value and 26% positive predictive value, as shown in our prior 
work, at 92% sensitivity and 20% specificity, with the lower bound 
of the classifier’s performance at 70% sensitivity and 48% specific-
ity. Classifier scores for the overall cohort were statistically indepen-
dent of patient age, tobacco use, nodule size, and chronic obstructive 
pulmonary disease diagnosis. The classifier also demonstrated incre-
mental diagnostic performance in combination with a four-parameter 
clinical model.
Conclusions: This proteomic classifier provides a range of probabil-
ity estimates for the likelihood of a benign etiology that may serve as 
a noninvasive, diagnostic adjunct for clinical assessments of patients 
with IPNs.
Key Words: Lung nodule, Proteomics, Molecular diagnostic, 
Biomarker.
(J Thorac Oncol. 2015;10: 629–637)
Lung nodules deemed indeterminate lack the features sug-gestive of benign etiologies1 and present clinicians with 
a diagnostic conundrum. Patient and practitioner balance a 
desire for the certainty of a diagnosis against the tolerance for 
the unknown, while assessing the risk and yield of an invasive 
procedure and the likelihood of malignancy. Achieving an early 
diagnosis of cancer remains a clinical imperative2 to improve 
the dismal 16% 5-year survival of nonsmall-cell lung cancer 
(NSCLC),3 and also to assuage the immediate concern and 
anxiety engendered among both patients and physicians upon 
the identification of such spots.4–6 The use of computed tomog-
raphy (CT) technology has grown annually with the number of 
nodules identified by chest CT scans approaching millions per 
year, most of which are benign.5 Patients with a nodule less than 
8 mm in size or having benign radiographic features may be 
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de l’Universite Ĺaval; Québec, Canada; ≠Integrated Diagnostics, Seattle, 
Washington; **Respiratory Institute, Cleveland Clinic, Cleveland, 
Ohio; ††Clinical Research Division, Fred Hutchinson Cancer Research 
Center, Seattle, Washington; ‡‡Division of Pulmonary and Critical Care 
Medicine, University of Washington, Seattle, Washington; §§Division of 
Pulmonary Sciences and Critical Care Medicine, Department of Medicine, 
Veterans Administration Eastern Colorado Healthcare System, University 
of Colorado Denver School of Medicine, Denver, Colorado; ║║Statistics 
Consultant, Carlsbad, California; ¶¶Thoracic Program, Vanderbilt-Ingram 
Comprehensive Cancer Center, Nashville, Tennessee; ≠≠Department of 
Veterans Affairs, Tennessee Valley Healthcare System, Nashville Campus, 
Nashville, Tennessee.
Disclosure: The authors declare no conflict of interest.
All authors made substantial contributions to the concept and design of the 
article; the acquisition, analysis, and interpretation of the data; participated 
in the drafting and revision of the article critically for important intellectual 
content; and gave their final approval of the version to be published.
Supported by National Institutes of Health grants NCI EDRN 5UO1CA 
152662 (P.P.M.), NCI EDRN 5U01CA111295-07 (H.I.P.), NCI 
1R21CA156087-01 (A.V.), UO1 CA086137 (W.N.R.), the Stephen A. 
Banner Lung Cancer Foundation (H.I.P.), and Integrated Diagnostics.
Address for correspondence: Pierre P. Massion, MD, Thoracic Program, 
Vanderbilt Ingram Cancer Center, Division of Allergy Pulmonary and 
Critical Care Medicine, Vanderbilt University Medical Center, PRB 640, 
2220 Pierce Avenue, Nashville, Tennessee 37232. E-mail: pierre.massion@
vanderbilt.edu
ORIgINAL ARTICLE
630 Copyright © 2015 by the International Association for the Study of Lung Cancer
Vachani et al. Journal of Thoracic Oncology ®  •  Volume 10, Number 4, April 2015
managed expectantly by serial CT scan surveillance.1 However, 
those with larger nodules may embark on a diagnostic odys-
sey,7 including positron emission tomography (PET), transtho-
racic needle aspiration, bronchoscopic biopsy, and/or surgery.1 
Therefore, innovative strategies to identify benign lung nodules 
may mitigate the diagnostic burden of those considered indeter-
minate, by providing complementary data for decision-making, 
minimizing surgical resection of benign processes,8 and manag-
ing more lung nodules by radiographic surveillance.
Extensive efforts to classify pulmonary nodules using 
molecular biomarkers, such as DNA, RNA, and proteins, have 
yielded novel insights into lung cancer pathogenesis, with most 
having been focused largely on identifying malignant rather 
than benign lung nodules.2,9–17 Proteins are attractive as bio-
markers because they are the dynamic, functional molecules 
acting in cell communications,18 with those of greatest interest 
often being in low abundance in plasma or serum. Therefore, 
advances in bioinformatics are at the core of recent progress 
in the development of diagnostic biomarker classifiers.19 The 
current enthusiasm for introducing biomarkers into practice 
has also heightened expectations for rigor in their validation as 
diagnostic tools for a targeted or intended use population.20
Our prior work21 applied multiple reaction monitoring mass 
spectrometry22,23 for the discovery and initial validation of a clas-
sifier incorporating plasma protein expression levels to differenti-
ate benign and malignant pulmonary nodules with 90% negative 
predictive value (NPV). In this study, we performed a validation 
of a multiprotein plasma classifier that prioritizes the diagnos-
tic parameters of sensitivity and NPV to identify likely benign 
lesions in patients presenting with 8 to 30 mm lung nodules.
MATERIALS AND METHODS
Validation
The study conforms to Institute of Medicine guidelines20 
(Supplemental Table 4, Supplemental Digital Content, http://
links.lww.com/JTO/A773) and the Standards for Reporting of 
Diagnostic Accuracy (STARD) criteria for reporting studies 
of diagnostic accuracy (Supplemental Table 5, Supplemental 
Digital Content, http://links.lww.com/JTO/A773).24 Protein 
expression analyses and computational procedures were 
performed in a clinical laboratory adhering to the Clinical 
Laboratory Improvement Amendments of 1988.20
Study Design and Oversight
The overall objective was to validate the performance 
of an 11-protein classifier in identifying lung nodules with 
likely benign (i.e., nonmalignant) etiologies (Supplemental 
Materials, Supplemental Digital Content, http://links.lww.
com/JTO/A773), yielding a range of probability estimates 
for use as a diagnostic adjunct in clinical assessments. 
A  retrospective, case-control study utilized multiple reaction 
monitoring mass spectrometry to analyze archival plasma 
samples from subjects enrolled in clinical studies approved 
by the Ethics Review Board or Institutional Review Boards 
at multiple institutions, using a blinded data analysis strat-
egy. Management of clinical data complied with the Health 
Insurance Portability and Accountability Act of 1996.
Study Inclusion and Exclusion Criteria
The subject inclusion criteria were a minimum age of 40 
years and any smoking history. The radiologic and pathologic 
criteria for lung nodule inclusion were a diameter between 8 
to 30 mm, a histopathologic diagnosis of NSCLC or a benign 
process, or a clinical diagnosis of a benign etiology based on 
stability in size and appearance for 2 years after the baseline 
CT scan. The subject exclusion criteria included the lack of 
nodule size or histopathologic diagnosis, follow-up for less 
than 2 years, or a diagnosis of small-cell lung cancer. The 
subjects’ spirometry data and the global initiative for chronic 
obstructive lung disease criteria25 were used to define the pres-
ence and severity of chronic obstructive pulmonary disease 
(COPD). The cancer and benign subgroups were matched for 
age, gender, smoking history, and nodule size.
Lung Nodule Protein Expression 
Classifier and Proteomic Analysis
The classifier consists of five diagnostic and six normal-
ization proteins (Table 1), which were fully defined, or “locked-
down,” before sample analysis. The five diagnostic proteins were 
refined from the 13 proteins previously shown to discriminate 
benign and malignant lung nodules21 using stable isotope stan-
dards (Supplemental Materials, Supplemental Digital Content, 
http://links.lww.com/JTO/A773). The six normalization proteins 
were identified to reduce preanalytical and analytical variations 
in mass spectroscopic protein quantification.25a Plasma protein 
expression assays were performed as previously described21 using 
methods incorporating stable isotope standards (Supplemental 
Materials, Supplemental Digital Content, http://links.lww.com/
JTO/A773).
Data Analysis
The first objective was to validate the overall perfor-
mance of the classifier (Table 1) in identifying benign nodules, 
using the method of the partial area under the curve (pAUC).26 
This objective required that the lower 95% confidence bound 
of the pAUC bounded by a sensitivity of 0.8 be higher than 
the corresponding pAUC (0.02) of a nonperforming classifier. 
The second objective was to validate the performance of the 
classifier in identifying benign nodules at predefined refer-
ence values using binomial testing. This objective required 
that the lower 95% confidence bound of the fraction of benign 
samples among samples whose scores were less than or equal 
to the corresponding reference values be higher than the frac-
tion of benign samples in the study. The fixed-sequence proce-
dure27,28 was used to control the overall multitesting error rate 
(α = 0.05) in the study. Statistical analyses were performed 
using the MannWhitney and Fisher’s exact tests.
RESULTS
Study Cohort
Plasma specimens from 195 subjects with lung nodules 
at four institutions in different geographic regions of North 
America initially satisfied the study inclusion criteria, which 
included a minimum subject age of 40 years, but no stipulated 
smoking status or pack-year history. Thirty-two candidate 
631Copyright © 2015 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 10, Number 4, April 2015 Proteomic Classifier for Benign Lung Nodules
samples were excluded due to clinical criteria, and an addi-
tional 22 samples were excluded based on laboratory criteria. 
A total of 141 subjects satisfied all clinical and laboratory cri-
teria, including 78 with cancer and 63 with benign diagnoses, 
demonstrated no overlap with those involved in the classifier’s 
development, and were included in the data analysis (Fig. 1 
and Table 2). There were no statistically significant differences 
in subject age, gender, and smoking history or lung nodule 
size between the cancer and benign groups.
Identification of Likely Benign Lung Nodules
The use of biomarkers for diagnostic purposes requires 
validation of the classifier’s performance,20 including the defi-
nition of the clinically relevant performance range to impact 
decision-making. Based on the plasma measurements of five 
diagnostic and six normalization proteins, the protein expres-
sion classifier yields a score from 0 to 1, with each value asso-
ciated with a sensitivity and a specificity, and lower scores 
associated with a higher probability of a benign etiology.21
The overall performance of the classifier in identifying 
benign nodules was validated with a lower 95% confidence 
bound for the pAUC of 0.026, which was greater than the 
targeted pAUC of 0.02 (Fig. 2 and Supplemental Materials, 
Supplemental Digital Content, http://links.lww.com/JTO/
A773). The performance of the classifier in identifying 
benign nodules at predefined reference values was tested 
individually in an increasing, stepwise manner and validated 
up to a reference value of 0.47 (Supplemental Materials, 
Supplemental Digital Content, http://links.lww.com/JTO/
A773). As shown in Figure 2, the sensitivity of the classifier 
increases above 70% at 0.47, as the reference values decrease 
toward the upper-right portion of the receiver operating char-
acteristics (ROC) curve.
The NPV was determined for each reference value by 
incorporating the prevalence of NSCLC in the target popula-
tion with 8 to 30 mm lung nodules, as high NPVs are use-
ful in identifying the absence of malignancy,29 e.g., benign 
nodules. Due to the lack of a consensus estimate of cancer 
prevalence for pulmonary nodules,30–33 a population-based 
weight-adjusted NSCLC prevalence of 23.1% was used, incor-
porating data from a national, multicenter chart review study 
of patients with indeterminate pulmonary nodules (IPNs, n 
= 377; unpublished data) and the National Lung Screening 
Trial34 (Supplemental Materials, Supplemental Digital 
Content, http://links.lww.com/JTO/A773). The NPV also 
increases from 84% at a reference value of 0.47 to 90% at a 
reference value of 0.36 (Fig. 2B), corresponding to sensitivity 
and specificity of 92% and 20%, respectively (Supplemental 
Fig. 4, Supplemental Digital Content, http://links.lww.com/
JTO/A773). The reference value-specific NPVs may be asso-
ciated with potential false-negative results, possibly resulting 
in malignant nodules being misclassified as likely benign, as 
shown in Supplemental Table 7 (Supplemental Digital Content, 
http://links.lww.com/JTO/A773). No single or combination of 
clinical parameters was identified that distinguished a given 
lung nodule sample in the study cohort as a potential “false-
negative” result, using either 0.47 or 0.36 as a reference value.
Classifier Independence of NSCLC Predictors
The cancer and benign groups were matched for age, 
pack-years, and nodule size, similar to what was done in the 
discovery and initial validation of the classifier proteins.21 
This enabled further assessment of the relationship of the 
classifier score to these clinical parameters. With respect 
to age, smoking history pack-years, and nodule size, none 
of these parameters correlated with the classifier scores 
TABLE 1.  Lung Nodule Protein Expression Classifier Diagnostic and Normalization Proteins
Term Name Value
α Constant −1.62
Proteins
  Diagnostic Coefficient, β Power, λ
   ALDOA_Human Fructose-1,6-bisphosphate aldolase −0.47 −0.61
   COIA1_Human Collagen alpha-1(XVIII) chain −2.47 −0.23
   FRIL_Human Ferritin light chain −0.86 0
   Lg3BP_Human galectin-3-binding protein −0.90 −0.63
   TSP1_Human Thrombospondin-1 −0.33 0.02
   COIA1 × FRIL Interaction term −1.23
  Normalization
   C163A_Human Scavenger receptor cysteine-rich type 1 protein M130 —
   gELS_Human gelsolin —
   LUM_Human Lumican —
   MASP1_Human Mannan-binding lectin serine protease 1 —
   PEDF_Human Pigment epithelium-derived factor —
   PTPRJ_Human Receptor-type tyrosine-protein phosphatase —
Shown are the five diagnostic proteins and one interaction term composed of COIA1 and FRIL and their respective coefficients, β, in the logistic regression classifier equation and 
their respective power, λ, in the BoxCox transformation (Supplemental Materials, Supplemental Digital Content, http://links.lww.com/JTO/A773) and also the six proteins used for data 
normalization25a Supplemental Materials, Supplemental Digital Content, http://links.lww.com/JTO/A773).
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(Supplemental Fig. 5 and Table 8, Supplemental Digital 
Content, http://links.lww.com/JTO/A773), which is consis-
tent with our previous results.21
COPD Status and Classifier Scores
Because COPD is a major risk factor for lung cancer,35 
the potential impact of a concurrent COPD diagnosis on clas-
sifier scores was determined. Spirometry data were available 
for 54 (45%) of the 121 subjects with a history of tobacco use, 
including 33 with a cancer diagnosis and 21 with a benign 
diagnosis (Fig. 3A). There was no difference between the clas-
sifier scores in subjects with malignant lung nodules without 
or with COPD (Fig. 3B). Similarly, there was no difference 
observed for classifier scores in subjects with benign lung 
nodules in the absence or presence of COPD.
Incremental Diagnostic Value
To illustrate the potential added diagnostic value of 
the protein expression classifier to the clinical assessment of 
patients with lung nodules, a four-parameter clinical model 
Clinical Criteria, n=32
age, n=5
nodule size, n=4
other cancer, n=4
post-surgery, n=16 
duplicate, n=3 
n=141 
NSCLC, n=78 
Benign, n=63
Laboratory Criteria, n=22
depletion QC, n=11 
quality control, n=1
analytical range, n=10 
n=163
NSCLC, n=85
Benign, n=78
n=195
NSCLC, n=113
Benign, n=  82
FIGURE 1.  Flow chart of validation study plasma sample 
availability and exclusions based on clinical and laboratory 
criteria. The participating centers (n = 4) identified 195 
plasma samples from 195 subjects initially satisfying the study 
inclusion criteria. After completion of clinical data monitor-
ing, 32 candidate samples were excluded due to subject age 
less than 40 years; nodule size less than 8 mm or larger than 
30 mm; nodule cancer pathology other than NSCLC; plasma 
sample collection after surgery; or provision of duplicate 
samples from the same subjects. An additional 22 samples 
were excluded after sample analysis based on laboratory 
criteria including depletion column quality control, mass 
spectrometry quality control, or a classifier result outside of 
the validated analytical range.21 A final total of 141 samples 
from 141 subjects satisfied the prespecified clinical and labo-
ratory criteria, including 78 cancer and 63 benign samples, 
and were included in the data analysis.
TABLE 2.  Clinical Characteristics of Subjects and Lung 
Nodules
Characteristics
Validation Study (n=141)
Cancer Benign P Value
Subjects 78 63
Age (year)a 65 (59–72) 65 (56–73) 0.85b
gender 0.18c
 Male 35 36
 Female 43 27
Smoking history
 Status 0.88c
  Neverd 11 9
  Former 48 41
  Current 19 13
  Pack-yeara,e 40 (30–60) 30 (21–63) 0.33b
Lung nodules
  Size (mm)a 14 (12–16) 15 (10–17) 0.67b
  Source 0.01c
  IUCPQ 3 11
  Mayo Clinic 18 16
  New York 32 13
  Vanderbilt 25 23
 Histopathology
  Benign diagnosis
   granuloma — 27
   No malignancyf — 10
   Hamartoma — 8
   Inflammationg — 3
   Pneumonia — 2
   Scar — 2
   CT surveillanceh — 4
   Otheri — 7
  Cancer diagnosis
   Adenocarcinoma 67 —
   Squamous cell 7 —
   Large cell 2 —
   Mixed 2 —
Participating sites included the Institut Universitaire de Cardiologie et de Pneumologie 
de Québec (IUCPQ), the Mayo Clinic, New York University, and Vanderbilt University.
aData shown are median values with quartile ranges indicated in parentheses.
bStatistical analyses were performed using the MannWhitney test
cStatistical analyses were performed using Fisher’s exact test.
dA never smoker is defined as an individual who has a lifetime history of smoking 
less than 100 cigarettes.
ePack-years are defined as the product of the total number of years of smoking and 
the average number of packs of cigarettes smoked daily among smokers only; one cancer 
sample and one benign sample were missing pack-year data.
fReported as no evidence of malignancy.
gReported as chronic inflammation or inflammatory changes.
hStable lung nodule on CT follow-up.
iOther categories include bronchiolitis obliterans organizing pneumonia, chondroid 
lesion, emphysema, sclerosing hemangioma, interstitial pneumonia, intra-alveolar 
hemorrhage, and necrosis with hemosiderophages.
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composed of patient age, gender, and smoking history pack-
years together with lung nodule size (clinical) and a model 
combining the clinical model with the protein expression 
classifier (clinical + classifier) were evaluated, as shown in 
Figure 4. The classifier demonstrated an area under the curve 
(AUC) of 0.615 (95% confidence interval [CI]: 0.524, 0.707), 
which was greater than that of the clinical model which showed 
an AUC of 0.591 (95% CI: 0.492, 0.678), whereas the AUC of 
the combined clinical + classifier model was 0.634 (95% CI: 
0.530, 0.724). Similarly, the pAUC of the clinical + classifier 
model was 0.062 (95% CI: 0.035, 0.088) and greater than the 
pAUC of 0.041 (95% CI: 0.022, 0.062) for the clinical model 
alone. The clinical + classifier model significantly improved 
upon the performance of the clinical model alone based on the 
likelihood ratio test (p = 0.025). The integrated discrimination 
improvement index, a metric for evaluating the incremental 
diagnostic value of biomarkers,36 for the clinical + classifier 
model was 0.041 (95% CI: 0.006, 0.076; p = 0.021). These 
data suggest that the protein expression classifier result may 
augment the diagnostic performance of clinical parameters 
used by physicians to assess lung nodules.
DISCUSSION
Although most lung nodules are benign,5 the deci-
sion to pursue serial CT scan surveillance is often difficult 
for those characterized as indeterminate (Supplemental Table 
3, Supplemental Digital Content, http://links.lww.com/JTO/
A773).1 To address the need for diagnostic adjuncts to the 
clinical predictors of malignancy, our prior work identified a 
panel of plasma proteins that discriminates benign from malig-
nant lung nodules based on high sensitivity and high NPV and 
involves molecular pathways implicated in lung cancer. This 
study demonstrates successful validation of a protein expres-
sion classifier using an independent plasma sample set, yield-
ing a range of NPVs to estimate the probability that a patient’s 
lung nodule is due to a benign, i.e., nonmalignant, etiology.
By incorporating the expression values of 11 plasma 
proteins quantified by mass spectrometry, the classifier yields 
a score that may be translated into a probability that an IPN is 
benign. Such a probability may be useful to discriminate nod-
ules that are benign from those that are indeterminate at the 
time of initial assessment.1 The classifier includes five diagnos-
tic proteins that play roles in diverse signaling pathways impli-
cated in homeostasis and lung cancer pathogenesis. Expression 
of fructose-1,6-bisphosphate aldolase, an enzyme regulating 
diverse cellular functions, is upregulated in adenocarcinoma 
tissues and correlates with the metastatic potential of squa-
mous cell carcinoma.37,38 Collagen alpha-1 (XVIII) chain is an 
extracellular matrix protein constituent of vascular and epithe-
lial basement membranes whose expression is strongly associ-
ated with poor outcomes in NSCLC.39 Downregulation of the 
expression of ferritin light chain identified in the early stages of 
squamous cell carcinoma suggests its potential as a biomarker 
for early diagnosis.40 Tissue expression of galectin-3-binding 
protein, which is implicated in angiogenesis and cell adhesion, 
motility and invasion, correlates with poor survival rates in 
lung cancer patients.41,42 Thrombospondin-1 is an endogenous 
angiogenesis inhibitor previously implicated as a circulating 
diagnostic biomarker discriminatory for lung cancer.43,44 The 
141 validation study plasma samples analyzed, and the 247 
patient samples in our prior study, were representative of the 
B 
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0.47 
0.39 
0.36 
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PPV PPV PPV PPVNPV NPV NPV NPV
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FIGURE 2.  Protein expression classifier validation. The pro-
tein expression classifier yields a score between 0 and 1, with 
lower values associated with a higher probability of a benign 
etiology, based on the identification and quantification of spe-
cific plasma proteins (Supplemental Materials, Supplemental 
Digital Content, http://links.lww.com/JTO/A773). A, The sta-
tistical performance of the classifier was validated with a lower 
95% confidence bound for the partial area under the curve 
(pAUC) of 0.026, which was greater than the targeted pAUC 
of 0.02; the performance of the classifier was validated at 
predefined reference values from 0.38 to 0.47. Shown are the 
receiver operating characteristic (ROC) curves based on the 
raw (circles) and fitted (grey line) data, along with the ROC 
curve associated with chance (grey dashed line). The maxi-
mal classifier score in the study for use as a reference value 
to assign a likely benign classification was 0.47, using the 
fixed-sequence procedure.27,28 Therefore, the region bounded 
by the grey ROC curve and a sensitivity of 80% represents the 
classifier’s partial area under the ROC curve (AUC) (shaded 
in grey). The associated sensitivity and specificity values (%) 
for the reference value of 0.47 are indicated (dashed lines). 
Similar data for reference values of 0.39 and 0.36, which cor-
respond to NPVs of 87% and 90%, respectively, are indicated 
(dashed lines). B, A reference value is a specific score at or 
below which the classifier may assign a likely benign result to 
a given plasma specimen, based on the measured values of 
the classifier’s constituent proteins. Classifier scores between 
0.18 and 0.47 may be used as a reference value. Shown are 
the positive and negative predictive values (PPV and NPV, 
respectively) for classifier reference values of 0.36, 0.39, and 
0.47 using cancer prevalences of 15%, 20%, 23%, and 25%. 
The value of 0.47 is shown based on the prespecified criterion 
for validation of the classifier using the fixed sequence proce-
dure; and the values of 0.36 and 0.39 are shown to illustrate 
a diagnostic performance of 90% NPV and an intermediate 
value, respectively.
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classifier’s target population.21 Achieving the first-validation 
objective based on the partial AUC of the ROC curve enabled 
optimization of the classifier’s sensitivity, and achieving the 
second-validation objective defined the range of classifier 
scores used to derive the NPVs, based on the associated sen-
sitivity and a weight-adjusted estimate of NSCLC prevalence 
for the target population. The importance of cancer prevalence 
on NPV was demonstrated by comparing the classifier NPVs 
based on the observed prevalence in the study cohort to the 
weight-adjusted prevalence estimated for the target population 
(Supplemental Fig. 4, Supplemental Digital Content, http://
links.lww.com/JTO/A773). This study’s cancer prevalence of 
55% is artifactually high given the case-control study design 
and is not representative of the cancer prevalence in the overall 
population of patients with IPNs. By contrast, use of the 23% 
cancer prevalence estimate for the target population allowed 
the calculation of NPVs (for the range of classifier reference 
values) that would more likely be observed in clinical practice. 
The potential impact of lower or higher prevalence of NSCLC 
on the protein expression classifier is shown in Figure 2B, dem-
onstrating that a lower cancer prevalence increases the classi-
fier’s NPV at each reference value, whereas a higher cancer 
prevalence decreases its performance. By contrast, the corre-
sponding low positive predictive values based on the associ-
ated specificities were anticipated due to the prioritization of 
identifying benign rather than malignant nodules. Thus, the 
proteomic analysis of a patient’s plasma based on the classi-
fier may be used to derive a probability, ranging from an NPV 
of 84% that a given individual’s lung nodule is likely due to a 
benign etiology.
Several aspects of the data suggest that the protein 
expression classifier may be a useful diagnostic adjunct to 
the current paradigm for assessing indeterminate lung nod-
ules. There was no correlation between classifier scores and 
the clinical parameters of age, smoking history pack-years, 
or nodule size for this cohort, which was also previously 
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Range p-value n Median 
Interquartile 
Range p-value 
Gender 
Male 35 0.554 (0.474, 0.656) 0.527* 36 0.487 (0.342, 0.618) 0.868* 
Female 43 0.519 (0.428, 0.672)  27 0.468 (0.386, 0.540)  
Smoking 
Status 
Never 11 0.544 (0.394, 0.704) 0.623** 9 0.386 (0.363, 0.462) 0.064** 
Former 48 0.542 (0.471, 0.668)  41 0.519 (0.384, 0.643)  
Current 19 0.506 (0.464, 0.638)  13 0.428 (0.371, 0.540)  
COPD§
Yes 12 0.572 (0.506, 0.658) 0.410* 6 0.554 (0.386, 0.650) 0.756* 
No 21 0.516 (0.458, 0.665)  15 0.565 (0.452, 0.676)  
GOLD§
No COPD 21 0.516 (0.458, 0.665) 0.484** 15 0.565 (0.452, 0.676) 0.484** 
1 4 0.540 (0.435, 0.621)  2 0.689 (0.524, 0.854)  
2 7 0.571 (0.519, 0.659)  4 0.485 (0.374, 0.617)  
3 1 0.714 (0.714, 0.714)  0    
4 0    0    
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FIGURE 3.  Distribution of classifier scores 
between cancer and benign histopathol-
ogy by tobacco use and chronic obstruc-
tive pulmonary disease (COPD). A, Shown 
are the correlations of classifier scores by 
subject gender, tobacco use history, and 
COPD subgrouped by the global initia-
tive for chronic obstructive lung disease 
(GOLD) classification system for malig-
nant and benign lung nodules. (Statistical 
analyses were performed using either the 
MannWhitney test* or the KruskalWallis 
test.** Data provided only for those 
nonsmoking subjects satisfying the GOLD 
definition of COPD.§) B, Box plots of clas-
sifier scores for subjects without and with 
COPD in association with lung nodules, 
with either a diagnosis of NSCLC (cancer) 
or a benign etiology (benign), demonstrate 
no statistically significant impact of COPD 
on classifier scores.
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demonstrated for this biomarker panel.21 The independence of 
the classifier from these clinical predictors enabled it to aug-
ment the diagnostic performance of a four-parameter clini-
cal model as demonstrated by an increase in the AUC of the 
combined model. The addition of other clinical and imaging 
parameters, such as nodule location, shape, or structure, may 
further augment the performance of such models. The lack 
of correlation between COPD global initiative for chronic 
obstructive lung disease status and classifier scores suggests 
that the classifier’s clinical performance may be minimally 
influenced by a patient’s concurrent diagnosis of mild or mod-
erate COPD. Furthermore, the range of NPVs for the classi-
fier reference values has a minimum of 84%, correlating with 
a false-negative rate (FNR) of 16% or lower; these classifier 
performance data compare favorably with the 4% to 28% FNR 
for quantitatively interpreted PET scans, the 10% to 30% FNR 
for transthoracic needle biopsy, and the 30% to 70% FNR for 
bronchoscopic biopsy.1
The potential limitations of this study derive from 
specifics of the experimental design relating to the classifier 
performance priorities and molecular biomarkers. As illus-
trated by the classifier ROC curve and the associated AUC 
and pAUC, the developmental prioritization of sensitivity 
allowed us to develop a classifier with high NPVs, which 
allows for the accurate identification of a likely benign lung 
nodule. However, the emphasis on sensitivity and high NPV 
throughout the discovery and validation of the classifier’s 
constituent proteins yielded a specificity ranging from 48% 
to 20% for NPVs ranging from 84% to 90%, respectively, 
demonstrating that the classifier may identify approximately 
half of the lung nodules that are benign. Therefore, a higher 
probability of an accurate assignment of a nodule as likely 
benign is accompanied by a lower proportion of nodules with 
that probability. Clinicians may need to consider this perfor-
mance compromise for the classifier, not only in comparison 
with similar issues with other diagnostic modalities, but also 
with respect to their potential morbidities. In addition, the use 
of archival samples from academic centers, though represen-
tative of the target population, may raise questions about the 
classifier’s prospective performance in the general population. 
The Institute of Medicine guidelines recognize and sanction 
the use of archival biospecimens due to the inherent difficul-
ties in their acquisition and their limited availability.20 This 
limitation is further mitigated for the validation cohort by the 
analysis of samples from geographically dispersed centers 
with diverse patient populations, including two not participat-
ing in the classifier’s discovery. Nevertheless, future evalua-
tions of the proteomic expression classifier in prospective lung 
nodule studies may clarify some of these performance issues. 
Additional limitations in the study cohort include the relative 
preponderance of adenocarcinoma among the cancer group, 
the lack of granuloma histologic subtyping, and the size of the 
study subcohort demonstrating the lack of an impact of COPD 
status on classifier scores; however, the number of subjects in 
the validation compares favorably with other proteomic inves-
tigations of COPD biomarkers.45–47
In summary, this work validates the performance of a 
proteomic classifier that identifies likely benign lung nodules 
Model 
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Clinical +
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 Classifier
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0.615 (0
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pAUC
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FIGURE 4.  Incremental diagnostic value of the protein 
expression classifier to a clinical lung nodule prediction 
model. Shown are the respective ROC curves for the clini-
cal model48 alone (grey dashed line), the protein expression 
classifier alone (black dashed line), and the model combin-
ing the protein expression classifier and the clinical model 
(solid line). Model performance for the clinical models was 
evaluated based on 1000 bootstrappings. Area under the 
ROC curve (AUC) and partial area under the curve (pAUC) 
at 80% sensitivity (shaded in grey) were calculated with 
bootstrap bias-corrected 95% confidence intervals (CI). The 
clinical model was composed of gender and the continuous 
variables of subject age and smoking history in pack-years 
(PKY) together with lung nodule size in a logistic regres-
sion model (Supplemental Materials, Supplemental Digital 
Content, http://links.lww.com/JTO/A773). The clinical plus 
classifier model included an additional parameter—the pro-
tein expression classifier score. Of the 141 subjects and lung 
nodules in the validation study cohort, one cancer sample 
and one benign sample were removed from the analysis due 
to missing PKY data; therefore, 139 samples were fitted in the 
logistic regression models, first with the clinical model alone 
and then with the clinical plus classifier model. The clinical 
model alone yielded an AUC of 0.591, whereas the clinical 
plus classifier model yielded an AUC of 0.634. The clinical 
model alone yielded a pAUC of 0.041, whereas the clinical 
plus classifier model yielded a pAUC of 0.062.
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with a high NPV, in patients with a minimum age of 40 who 
present with a lung nodule 8 to 30 mm in diameter. The data 
suggest that the classifier may serve as a noninvasive, objec-
tive, biology-based, and quantitative diagnostic adjunct to 
current modalities, such as PET scan, that may help decrease 
the number of lung nodules categorized as indeterminate 
and facilitate their diagnostic triage to surveillance imaging. 
Incorporation of the classifier result early during the initial 
clinical assessment may provide assurance about the likeli-
hood of a benign etiology, with further reassurance provided 
by radiographic stability on subsequent chest CT scans. The 
noninvasive advantage of a blood-based molecular diagnostic 
test for lung nodules may preclude a diagnostic odyssey7 of 
successively more invasive procedures, reassure patients and 
physicians about surveillance decisions, decrease concern and 
anxiety about malignancy, and mitigate the morbidity and 
costs associated with biopsies and surgery that unfortunately 
often lead to benign diagnoses.1
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